Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGFBR2-KO CD70-CAR NK cells
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
TGFBR2-KO CD70-CAR NK cells is an investigational allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by the M.D. Anderson Cancer Center. Derived from umbilical cord blood, these NK cells are genetically engineered to express a CAR targeting CD70, a tumor-associated antigen highly expressed in clear cell renal cell carcinoma (ccRCC), mesothelioma, and osteosarcoma. To overcome the immunosuppressive tumor microenvironment, the cells undergo CRISPR/Cas9-mediated knockout of the transforming growth factor-beta receptor type 2 (TGFBR2) and the cytokine-inducible SH2-containing protein (CISH), which are negative regulators of NK cell function. The therapy is further enhanced by the ectopic expression of Interleukin-15 (IL-15) to improve cell persistence and proliferation, and includes an inducible caspase 9 (iC9) safety switch for controlled elimination of the cells if toxicity occurs.
- Other names
- Allogeneic TGFBR2-knockout CD70-targeted CAR NK cellsTGFBR2 KO CD70 CAR NKTGFBR-2 KO CD70 CAR NKTGFBR 2 KO CD70 CAR NKCISH-KO CD70-CAR NK cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on TGFBR2-KO CD70-CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGFBR2-KO CD70-CAR NK cells.